EGFR and non-small cell lung carcinoma: The most common EGFR mutations reported so far in the case of non-small cell lung cancer (NSCLC) are the deletion of exon 19 and substitution mutation (L858R) at exon 21, leading to constitutive tyrosine kinase activity independent of ligand binding4.